Oasis Therapeutics

Oasis Therapeutics is a clinical-stage biopharmaceutical company based in Hong Kong that specializes in developing innovative treatments for central nervous system (CNS) disorders and acute pain. The company utilizes its proprietary Oasis Prodrug Platform to engineer prodrugs with optimized pharmacokinetic properties, aiming to improve the safety and efficacy of established therapeutic agents. Its lead program, OTX-2001, is a long-acting non-opioid analgesic currently in Phase 1 clinical trials for the management of post-operative pain. Additionally, the company is advancing OTX-1001, a prodrug of ketamine, for the treatment of psychiatric conditions such as treatment-resistant depression. Oasis Therapeutics aims to address significant unmet medical needs by providing more manageable and effective therapeutic options for patients worldwide.